|
Market Closed -
Xetra
11:35:48 2026-09-30 EDT
|
5-day change | 1st Jan Change | ||
| 21.39 EUR | -1.20% |
|
-2.64% | +1.66% |
| 09-30 | European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading | MT |
| 09-30 | Major drugmakers turn to China for licensing deals | RE |
| Market Cap | 73.41B 97.46B 85.82B 81.31B 138B 9,345B 140B 973B 374B 4,777B 366B 358B 15,316B | P/E 2026 * |
14.2x | P/E 2027 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 94.65B 126B 111B 105B 178B 12,049B 181B 1,254B 483B 6,159B 472B 462B 19,747B | EV / Sales 2026 * |
2.79x | EV / Sales 2027 * | 2.59x |
| Free-Float |
92.75% | Yield 2026 * |
3.8% | Yield 2027 * | 4.09% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Börse Stuttgart
| GS71 | Delayed | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
OTC Markets
| GLAXF | Delayed | |
|
Deutsche Boerse AG
| GS71 | Delayed |
Last Transcript: GSK plc
| 1 day | -1.20% | ||
| 1 week | -2.64% | ||
| 1 month | -1.56% | ||
| 3 months | -7.00% | ||
| 6 months | -9.67% | ||
| Current year | +1.66% |
| 1 week | 21.39 |  | 22.36 |
| 1 month | 20.62 | | 22.36 |
| Current year | 20.34 | | 26.14 |
| 1 year | 18.38 | | 26.14 |
| 3 years | 14.48 | | 26.14 |
| 5 years | 14.48 | | 27.23 |
| 10 years | 14.48 | | 27.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.20% | -2.64% | - | - | 97.46B | |
| -2.33% | +0.53% | +51.65% | +115.42% | 1,031B | |
| -1.06% | -1.65% | +42.78% | +69.98% | 638B | |
| -0.65% | -1.32% | +12.98% | +75.49% | 462B | |
| -2.66% | -1.87% | +73.13% | +41.15% | 359B | |
| -0.06% | -3.88% | +34.32% | +39.39% | 335B | |
| -0.79% | +2.01% | +19.82% | +27.79% | 273B | |
| -1.19% | -1.21% | +9.82% | +10.61% | 253B | |
| -0.50% | +3.80% | +49.37% | +56.84% | 228B | |
| -1.47% | -1.53% | +34.28% | +98.89% | 185B | |
| Average | -0.88% | -0.18% | +36.46% | +59.51% | 418.21B | |
| Weighted average by Cap. | -1.02% | -0.23% | +39.79% | +71.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.92B 45.03B 39.66B 37.57B 63.93B 4,318B 64.76B 450B 173B 2,207B 169B 165B 7,077B | 35.5B 47.13B 41.5B 39.32B 66.9B 4,519B 67.77B 470B 181B 2,310B 177B 173B 7,406B |
| Net income | 5.19B 6.89B 6.07B 5.75B 9.78B 661B 9.91B 68.8B 26.48B 338B 25.88B 25.32B 1,083B | 6.21B 8.24B 7.26B 6.88B 11.7B 790B 11.85B 82.29B 31.67B 404B 30.96B 30.28B 1,296B |
| Net Debt | 21.24B 28.2B 24.83B 23.53B 40.04B 2,704B 40.55B 282B 108B 1,382B 106B 104B 4,432B | 18.52B 24.58B 21.65B 20.51B 34.9B 2,357B 35.35B 245B 94.44B 1,205B 92.31B 90.3B 3,863B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-30 | €21.39 | -1.20% | 20,551 |
| 26-09-29 | €21.65 | -0.14% | 61,803 |
| 26-09-28 | €21.68 | +0.74% | 23,696 |
| 26-09-25 | €21.52 | -1.37% | 13,774 |
| 26-09-24 | €21.82 | -0.68% | 25,077 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GS71 Stock
Select your edition
All financial news and data tailored to specific country editions
